Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced the unexpected passing of its Chief Financial Officer, Richard Eisenstadt, on June 24, 2024. Following this event, the company's Board of Directors appointed Andrew Shutterly as the acting Chief Financial Officer, effective immediately. Shutterly, who has been with Altimmune since October 2020, previously served as Corporate Controller since February 2023 and has a background in accounting with experience at Meso Scale Diagnostics LLC and Deloitte. Altimmune will enter into an indemnification agreement with Shutterly similar to those with other executive officers. The company has also issued a press release expressing condolences and has begun the search for a permanent CFO replacement. Altimmune specializes in developing peptide-based therapeutics and is currently working on pemvidutide for obesity and NASH treatment.

Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced the unexpected passing of its Chief Financial Officer, Richard Eisenstadt, on June 24, 2024. Following this event, the company's Board of Directors appointed Andrew Shutterly as the acting Chief Financial Officer, effective immediately. Shutterly, who has been with Altimmune since October 2020, previously served as Corporate Controller since February 2023 and has a background in accounting with experience at Meso Scale Diagnostics LLC and Deloitte. Altimmune will enter into an indemnification agreement with Shutterly similar to those with other executive officers. The company has also issued a press release expressing condolences and has begun the search for a permanent CFO replacement. Altimmune specializes in developing peptide-based therapeutics and is currently working on pemvidutide for obesity and NASH treatment.